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Summary After curative resection for gastric adenocarcinoma, 103 patients, all with positive nodes, were
randomised so that 48 received adjuvant chemotherapy of epidoxorubicin (EPI) 75 mg m2 on day 1,
leucovorin (LV) 200 mg m-2 on days 1-3 and 5-fluorouracil (5-FU) 450 mg m-2 on days 1-3, every 21 days
for 7 months, whereas the remaining 55 did not. During the first year of observation, 21 control patients (38%)
and five treated patients (10%) had recurrences. After a follow-up period of 36 months, 12 of the treated
patients (25%) and only seven controls (13%) were still alive. At that point, the median survival was 13.6
months for the 55 untreated patients and 20.4 months for the 48 treated patients, a significant difference. We
found a survival advantage for patients treated with the EPI-LV-5-FU regimen and a consistent delay in the
appearance of recurrent or metastatic cancer. Acute toxicity was mild and treatment was well accepted by all
patients. There was no long-term toxicity or any cardiac toxicity. We conclude that this particular
chemotherapy, administered shortly after gastric resection, improves survival rate in node-positive gastric
cancer patients, even although final assessment of this particular adjuvant approach must await completion of
the trial.
Keywords: adjuvant chemotherapy; epidoxorubicin; 5-fluorouracil; gastric cancer; leucovorin; randomised trial
Gastric cancer represents the third most common cause of
cancer death in Italy (Decarli et al., 1988). Because the early
course of the disease is often silent, most patients present
with advanced disease. In the last decade, 17 000 new
patients were diagnosed but only 25% of these were
candidates for curative surgery. The prognosis of untreated
patients with gastric cancer is 4 months and this increases to
6 months for those undergoing palliative resection (Waxman,
1992). Despite standardisation of resection techniques,
extensive lymph node dissection and the use of mechanical
staplers for critical anastomoses, the results of surgical
resection alone in patients with locally advanced gastric
carcinoma are disappointing; in Western countries, including
Italy, the 5 year survival rate ranges from 5% to 15%, with a
median survival of only 8 months (Alexander et al., 1993).
The relatively high incidence of residual tumour after surgical
resection, disease spread to the peritoneal surface and rapid
development of systemic metastases are the major causes of
failure following surgery.
The purpose of adjuvant therapy is to enhance the efficacy
of primary surgery so as to eradicate malignant cells
disseminated before or at the time of surgery and to
suppress the growth of hidden micrometastases.
In therapeutic terms, radiation therapy is only minimally
effective in patients with gastric cancer (Balikdjian et al.,
1980) and few studies have evaluated radiation therapy alone
as an adjuvant to surgical resection in gastric cancer.
Because peritoneal and hepatic recurrence are common,
intraperitoneal post-operative chemotherapy is being investi-
gated at several centres, but this approach has yielded only
limited success in the last few years (Bleiberg et al., 1992).
Among combined regimens for systemic chemotherapy for
gastric cancer, the most widely used is the FAM combination
[5-fluorouracil (5-FU), doxorubicin and mitomycin C]
(Macdonald et al., 1980; Haim et al., 1982); a number of
FAM modifications, involving the replacement of mitomycin
with other drugs or of doxorubicin with epidoxorubicin, have
also been investigated (Ogawa et al., 1990; Havlin et al.,
1992). In addition, the combination ofetoposide, doxorubicin
and cisplatin (EAP) (Preusser et al., 1989) as well as the
biochemical modulation of 5-FU activity by the addition of
leucovorin (Bruckner et al., 1991; Kornek et al., 1992) have
proved highly efficacious. Recently, in a phase II study of
advanced gastric cancer treated with epidoxorubicin and
high-dose leucovorin plus 5-FU (EPI -LV-5-FU), we
obtained a response rate of 49% and a median response
duration of 13 months with a very low general toxicity (Neri
et al., 1993). These data would lead one to suppose that
treatments found to be active in advanced disease might also
be tested as adjuvant therapy in resectable gastric cancer.
The attempt to reduce recurrences and prolong survival in
patients with gastric carcinoma has led to intensive study of
adjuvant chemotherapy after surgical gastric resection by
cooperative groups and others (The Gastrointestinal Tumor
Study Group 1982; Engstrom et al., 1985; Coombes et al.,
1990; Estape et al., 1991). Although the overall results ofthese
trials failed to demonstrate a general advantage and no clear-
cut benefits have emerged from trials involving random
assignment to various adjuvant chemotherapy schedules
(Alexander et al., 1993), such an approach seemed to be
effective for certain subgroups of patients (de Braud et al.,
1992).
Promising results with the EPI -LV -5-FU combination in
advanced gastric cancer (Neri et al., 1993) prompted us to
test this schedule as adjuvant chemotherapy in a randomised
trial on resected, node-positive gastric cancer patients.
Patients and methods
Our experimental design took into account two basic factors.
Gastric cancer is a disease with a very poor prognosis and
survival for stages T3 and T4 range approximately from 3 to
15 months, with a very high mortality index in the first year
of follow-up; therefore, a clinical trial involving 100-120
patients seemed to us both reasonable and appropriate
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(Simon, 1985), and an interim analysis after 36 months of
follow-up adequate to reveal whether or not median survival
could be doubled.
The criteria for entry into the trial were: histologically
proven adenocarcinoma treated by potentially curative
surgery, Karnofsky score greater than 60 and past good
general health with no history of cardiac disorder or
congestive cardiac failure. Exclusion criteria were: previous
malignancy, previous chemotherapy or radiotherapy, evi-
dence of disease at the resection margins or contiguous organ
involvement. Moreover, all patients with negative lymph
node status (as determined pathologically) were considered
ineligible for this trial. Surgery was performed at each of the
participating centres and the following surgical procedures
were employed: gastric resection with limited lymphadenect-
omy of the perigastric lymph nodes (R-lA resection) or
additionally with selective lymph node dissection for all other
macroscopically suspicious nodes (R-lB resection); gastric
resection with an extensive en bloc resection of second-
echelon lymph nodes (R-2 resection).
In the 32 month period between May 1989 and December
1991, a total of 112 patients were reported by the
participating centres to have undergone resection for
histologically proven gastric carcinoma. During the 4- to 6-
week period between surgery and the beginning of the study
proper, more detailed case history and clinical evaluation
revealed that nine of these patients were ineligible to take
part in the study for the following reasons: two were found to
have TI NO tumours, two had had previous carcinomas,
three suffered from cardiac disorders and two declined to be
followed. Table I outlines clinical characteristics of patients
and their tumour stage. All patients were aware of the
investigational nature of the treatment and had given written
informed consent, in line with institutional regulations. Full
staging of patients was carried out before they entered the
trial. All subjects underwent chest radiology, liver ultrasono-
graphy and/or computerised tomography scanning, bone scan
and evaluation ofcardiac function by echocardiography, liver
and renal function tests and blood count. In the randomisa-
tion carried out 4-6 weeks following gastric resection,
patients were stratified by centre to receive either post-
operative chemotherapy (Table II) or control follow-up.
Patients in both groups were evaluated at 8 week intervals
during the first post-operative year and at 3 month intervals
Table I Clinical characteristics of patients
Treatment arm
Control Chemotherapy
(arm A) (arm B)
during the second and third years. Before each chemotherapy
cycle, a patient's white blood cell count (WBC) had to be
greater than 4000 mm3 and his platelet count greater than
120 000 mm3. All treatments were given on an outpatient
basis and continued for 7 months, unless discontinued at the
patient's request or because of unacceptable side-effects or
relapse. Before every course of treatment, haematological and
biochemical values were measured and dosages adjusted
accordingly. Only on day 1 did all treated patients receive
anti-emetic pretreatment with ondansetron 8 mg (i.v.) and
methylprednisolone 125 mg (i.v.). Toxicity was evaluated
according to World Health Organization criteria (Miller et
al., 1981). Post-operative survival was determined for all
patients and was measured from the date of randomisation to
death or last follow-up. Life-table estimates were computed
using life-table options from a univarate analysis and were
compared using the log-rank test and an estimate of the
hazard ratio (HR) provided with associated confidence
interval (SAS Institute, 1987).
Results
The present study reports the results of 103 randomised
patients. The percentage of the planned dose actually
delivered was calculated for all patients. A total of 321
chemotherapy cycles were recorded. Forty-three patients
(89%) received all of the planned seven cycles of the EPI-
LV -5-FU schedule. One patient developed severe myelosup-
pression and completed only five cycles, at an attenuated
dose. Three patients refused to go on with therapy after the
fourth cycle, and one relapsed after the third cycle and died 7
months after the onset of chemotherapy. The total
observation period extended over 36 months. In December
1994 the median survival time for the 55 untreated patients
was 13.6 months (range 2-36+). The 48 treated patients
achieved a median survival time of 20.4 months (7-36+), a
significant increase (P<0.01), and HRs calculated for the
whole period of observation support these findings (Table
III). In the control arm 48 out of 55 patients died because of
recurrence vs 36 out of 48 in the adjuvant EPI-LV-5-FU-
treated group. But if we consider only the period of
treatment, the difference between the groups in the number
of cancer recurrences is even more striking: 5/48 (10%) of the
treated group vs 21/55 (38%) in the control group (P<0.01).
Survival time and the proportion of patients alive by the end
of 36 months of observation are reported in Figure 1. Of the
48 patients with recurrence in the control arm, the liver was
the site of recurrence in 18 (36%), half of whom were noted
to have the liver as the only site of recurrence. The liver was
a site of metastatic cancer in only 7 (19%) of the 36
recurrences seen in the adjuvant chemotherapy arm. In no
Evaluable patients
Median age (range)
Sex
Male
Female
Site of primary tumour
Pylorus or antrum
Body
Cardia or fundus
T stagea
TI
T2
T3
T4
N stage
NI
N2
Surgery
R-IA resection
R- 1B resection
R-2 resection
Karnofsky score
<80
>80
55 48
63 (35-73) 61 (37-70)
39
16
19
25
11
5
27
22
19
36
18
30
7
23
32
aInternational Union Against Cancer (1987).
33
15
15
21
12
4
24
20
15
33
13
29
6
19
29
Table II Schema for chemotherapy following gastric resection for
cancer
Randomisation
Arm A: Control
Evaluate every 8 weeks for the first post-operative
year and every 3 months in the second and third
post-operative year
Arm B: Chemotherapy
Epidoxorubicin (EPI) 75 mg m-2 i.v. day 1
Leucovorin (LV) 200 mg m-2 i.v. days 1-3
5-Fluorouracil (5-FU) 450 mg m 2 i.v. days 1-3
Table III Hazard ratioa and confidence limits
Treatment Hazard LCLb UCLb
Arm A 2.17 1.29 3.66
Arm B 1.00 -
aAnalysis for 36 months offollow-up. b95% Confidence limits. Arm
A, controls. Arm B, treated patientsAdjuvant chemotherapy after gastric resection
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Table IV Toxicity according to World Health Organization grade
Grade Incidence ofgrade
0 1 2 3 4 3 or 4 toxicity (%)
Emesis 11 19 6 - -
Diarrhoea 12 17 16 3 - 3/48 (6.3)
Mucositis 7 12 25 4 - 4/48 (8.3)
Alopecia 9 11 28 - - -
Cardiac 18 26 4 - - - -
Hepatic 14 18 16 - -
Neurological 23 25 - - - -
Renal 24 20 4 -
Anaemia 17 19 11 1 - 1/48 (2.1)
Leucopenia 11 14 19 4 - 4/48 (8.3)
Thrombopenia 15 19 14
B+ (12/48, 25%)
+A++++A+ (7/55, 13%)
0 12 24 36
I
V.V
ARM A 55 43 22 12 8 7 7
ARM B 48 47 32 19 16 15 12
Time (months)
Figure 1 Survival distribution of patients following surgery. The
number of patients (risk set) is shown beneath the time axis. Arm
A, controls; arm B, treated patients.
case, however, did relapsed patients receive other than
supportive treatment since one of the objects of this study
was to establish patients' survival.
The toxicity scores per patient are listed in Table IV.
Gastrointestinal toxicity was mild: only three patients had
grade 3 diarrhoea and four mucositis; nausea and vomiting
were not major problems. Alopecia was frequent but it was
reversible in all patients after the end of treatment. The mean
total dose of EPI administered was 450 mg m-2 (range 225-
525 mg m-2) and no evidence of cardiac toxicity (WHO
grade > 3) was recorded. With regard to bone marrow
toxicity, the treatment led to a much greater suppression of
leucocytes and platelets, as well as to a non-significant
decrease in erythrocyte count. Myelosuppression tended to be
cumulative, with lower and more prolonged nadirs after five
cycles. Leucopenia (WHO grade 3 toxicity) affected only four
patients. None of our patients required hospitalisation for
sepsis, and the seven who experienced infections (mainly
pulmonary) were all manageable on an outpatient basis.
Discussion
Studies over the past few years seeking to define the role of
post-surgical adjuvant chemotherapy in gastric cancer have
yielded contradictory results (de Braud et al., 1992; Atiq et
al., 1993; Hermans et al., 1993), leaving the issue still
unresolved. However, the modulation of 5-FU by folinic acid
has led to the testing of promising new combinations in
advanced gastric cancer (Murad et al., 1993; Neri et al.,
1993).
Some preliminary data of ours (Neri et al., 1992) had
pointed to the ineffectiveness of post-surgical adjuvant
chemotherapy in terms of disease-free interval and survival,
for patients who at the time of surgery proved to be node
negative. Since the presence of lymph node involvement is a
highly unfavourable prognostic factor (Michelassi et al.,
1994), hence one requiring adjuvant treatment, we considered
node-positive patients as those who stood to benefit the most
from post-surgical chemotherapy. This approach is in line
with observations reported by other authors (The Gastro-
intestinal Tumor Study Group, 1982) who, with a therapeutic
scheme different from ours, singled out patients with more
advanced (T3-T4) gastric carcinomas as the ones likely to
profit from adjuvant treatment, provided its dose intensity
was high enough. At the same time, several investigators have
focused on standardising the surgical techniques used in this
pathology (Hermans et al., 1993; Bunt et al., 1994), since
lymph node status plays a crucial role in the prognosis and
choice of treatment. Moreover, starting from the observation
that the majority of patients are diagnosed with stages III
and IV gastric cancer, other researchers view preoperative
chemotherapy as a more than promising approach to the
integrated treatment of gastric cancer (Wilke et al., 1989;
Fink et al., 1993; Rougier et al., 1994), so much so that
preoperative chemotherapy appears to be an attractive tool
for clinical investigation in earlier stages of gastric cancer
(Wils et al., 1994).
In this study a survival advantage for patients treated with
EPI-LV-5-FU was achieved and adjuvant chemotherapy
was associated with a consistent delay in the appearance of
recurrent or metastatic cancer. The treated patient group,
moreover, had relatively fewer hepatic metastases than the
controls, which, in agreement with Coombes et al. (1990) and
Estape et al. (1991), suggests a protective effect of adjuvant
chemotherapy on blood-borne cancer dissemination. Acute
toxicity was mild and treatment was well tolerated by
patients, all of whom were treated on an outpatient basis.
Long-term toxicity was non-existent and no case of cardiac
toxicity was observed. We find these results sufficiently
encouraging that, even before the completion of our 5 year
follow-up, we have started using this adjuvant chemotherapy
schedule with all node-positive gastric cancer patients. At the
same time, we view as more promising candidates for
adjuvant treatment patients earlier than stage III, that is,
those with the lowest residual microscopic tumours after
surgery. Furthermore, to optimise the chances of positive
results we start treatment within 6 weeks after surgery and
select a therapeutic schedule that produces a high degree of
efficacy, with a grade of toxicity that is acceptable yet does
not compromise the optimum dose intensity of treatment.
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